Gene and cell therapies offer ground-breaking new opportunities for patients with rare and complex diseases.

Maximizing patient access to effective gene and cells therapies is a part of the RARE IMPACT initiative’s mission.

30 million Europeans are living with rare diseases and 80% of rare diseases are genetic in origin.

There are many challenges hampering patients’ access to gene and cell therapies; to date, the availability of these therapies is limited.

Gene and cell therapy availability – Jan ’20

• Available in ≤ 3 European markets: 5
• Withdrawn from market: 5
• Available in > 3 European markets: 3

EURORDIS has initiated a patient-focused collaboration that seeks to improve patients’ access to these therapies.